The Development of Small Molecule Inhibitors of the TWEAK-Fn14 Pathway in Glioblastoma Multiforme
Description
Glioblastoma multiforme is the most common and aggressive primary malignant brain tumor in adults, exhibiting a median survival of only 15 months after diagnosis. A significant challenge in treating GBM is the ability of glioma cells to invade normal brain tissue, escape surgical resection, and resist radiotherapy and chemotherapy. We have previously demonstrated that the TWEAK-Fn14 signaling axis plays an important role in glioma cell invasion and discovered a small molecule, L524-0366, that specifically disrupts the TWEAK-Fn14 interaction. However, low affinity limits L524-0366’s clinical feasibility. By utilizing structure-activity relationship analyses of L524-0366, we identified additional small molecules that may inhibit TWEAK-Fn14 signaling. Here, we identify five additional novel Fn14 signaling inhibitors that specifically inhibited TWEAK-Fn14 NF-κB-dependent signaling and suppressed TWEAK-induced glioma cell migration. Furthermore, we demonstrate that two molecules exhibit improved affinity for Fn14, two molecules showed binding to the TWEAK ligand but not Fn14, and one showed no binding to either TWEAK or Fn14. These molecules will be further tested for in vitro and in vivo functionality, and serve as foundations for additional medicinal chemistry for drug modifications.
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
2016-12
Agent
- Author (aut): Millard, Nghia Patrick
- Thesis director: Misra, Rajeev
- Committee member: Chang, Yung
- Committee member: Tran, Nhan
- Contributor (ctb): School of Life Sciences
- Contributor (ctb): School of Mathematical and Statistical Sciences
- Contributor (ctb): Barrett, The Honors College